PRECISESADS General Assembly
The next PRECISESADS project meeting will take place on the 8th – 9th of March, 2018 in Ascot, UK. AGENDA you can register for this event at https://www.surveymonkey.com/r/RWDBLRS
Esta web utiliza cookies propias y de terceros para mejorar nuestros servicios mediante el análisis de sus hábitos de navegación. Si continua navegando, consideramos que acepta su uso. Puede cambiar la configuración u obtener más información aquí.
The next PRECISESADS project meeting will take place on the 8th – 9th of March, 2018 in Ascot, UK. AGENDA you can register for this event at https://www.surveymonkey.com/r/RWDBLRS
“We are delighted to report that we have over-achieved our recruitment targets for this project. Patient recruitment can be especially difficult as patients are widely dispersed and may face issues, such as physical limitations, that can affect their ability to readily participate” says Prof Alarcón Riquelme. ‘Patients have been highly motivated and generously willing to
The second Datathon training took place in Brest together with the project SC meeting (4-5 October 2017). 23 researchers participated in this event kindly organized by Jacques-Oliver Pers from UBO.
PRECISESADS http://precisesads.eu/, an IMI funded project, has now recruited over 2000 people into its pan-European cross sectional clinical study of systemic autoimmune diseases such as rheumatoid arthritis and lupus. This milestone means that the project is well on track towards its goal of recruiting a total of 2 500 people from across 9 European countries.
Molecular Reclassification to Find Clinically Useful Biomarkers for Systemic Autoimmune Diseases
by phone: +34 958 715 500
by e-mail:
or fill in the form on contact page
This website reflects only the author’s views and neither IMI nor the European Commission are liable for any use that may be made of the information contained therein.
PRECISESADS receives support from the Innovative Medicines Initiative Joint Undertaking under grant agreement n° [115565], resources of which are composed of financial contribution from the European Union’s Seventh Framework Programme (FP7/2007-2013) and EFPIA companies’ in kind contribution.
Molecular Reclassification to Find Clinically Useful Biomarkers for Systemic Autoimmune Diseases